期刊文献+

人附睾蛋白4(HE4)在宫颈癌中的表达及临床意义 被引量:6

下载PDF
导出
摘要 目的探讨HE4在宫颈癌发生发展中的作用,并初步分析其与宫颈癌临床病理因素的关系。为寻求新的有效的宫颈癌血清标志物提供实验基础。方法采用免疫组织化学SP法检测正常宫颈组织30例、低度宫颈上皮内瘤变30例、高度宫颈上皮内瘤变30例、宫颈癌144例患者子宫颈中HE4的表达水平及分布。结果HE4在正常宫颈、低度宫颈上皮内瘤变、高度宫颈上皮内瘤变和宫颈癌组织的阳性表达程度不同。宫颈组织癌中HE4表达显著高于正常宫颈组织,差异具有统计学意义;而在正常宫颈、低级别、高级别CIN中的阳性表达程度存在有差异,但无统计学意义(26.3%、59.0%、67.3%,P=-0.181、P=-0.086)。HE4的阳性表达率与宫颈癌的肌层浸润深度、腹膜后淋巴结转移情况、高危型HPV感染等有相关陛,HE4表达与宫颈癌患者年龄、分娩次数、临床分期、病理分级无相关性(P〉0.05)。结论宫颈癌组织中的HE4表达显著高于正常宫颈组织。子宫颈癌是HE4高表达的肿瘤。HE4与子宫颈癌肌层浸润深度、腹膜后淋巴结转移情况、高危型HPV感染等有相关性,HE4可作为宫颈癌高危因素指标。
出处 《国际医药卫生导报》 2012年第17期2523-2527,共5页 International Medicine and Health Guidance News
  • 相关文献

参考文献8

  • 1Food Nutrition Physical Activity, and the prevention of cancer: a global perspective[M].lARC,1997: 301-308.
  • 2Anttila A, Pukkala E, Soderman B, et al. Effect of or- ganized screening on cervical cancer incidence and mor- tality in Finland, 1963-1995: Recent increase in cervi- cal cancer. 1999, 83 : 59-65.
  • 3Petterson F. FIGO .Annual report on the result of treat- ment in gynecologic cancer. Stockholm Radiumhemmet, 1991.
  • 4Petterson Fced, 22nd .Annual report on the results of treatment in gynecological caner, F IGO, 1994.
  • 5HellstrOm I, Raycraft J, Hayden-LedbetterM, et al. The HE4( WFDC2 ) protein is a biomarker for ovarian carcinoma [J].Cancer Res, 2003,63( 13): 3695-3700.
  • 6Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing pro- tease inhibitor domains with homology to whey acidic protein [J]. Biochem J, 2002, 368 ( Pt 1 ): 233-242.
  • 7Sharp JA, Lefbvre C, Nicholas KR. Molecular evolu- tion of monotreme and marsupial whey acidic protein genes [J]. Evol Dev, 2007, 9 ( 4): 378-392.
  • 8Nozaki K, Ogawa M, Williams JA, et al. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss[J]. Gastroenterology, 2008,134 (2) : 511-522.

同被引文献59

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1565
  • 2谭诗生,李杭,罗健,陈南江,宋毅,姜桂林,杨飞月.欧洲癌症研究与治疗组织研制的生活质量核心调查问卷第3版中文版生活质量调查问卷测评[J].中国临床康复,2006,10(4):23-27. 被引量:314
  • 3章文华.宫颈病变的诊治要点[M].北京:人民卫生出版社,2006:78-79.
  • 4Simmons AR, Baggerly K, Bast RC Jr. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas [J]. Oncology (Williston Park) ,2013,27(6) :548-556.
  • 5唐华.联合检测血清CA125、SCCA、HE4、CEA对宫颈癌诊疗价值的研究[J].医药前沿,2014,4(20):9-10.
  • 6Stiekema A, Boldingh QJ, Korse CM. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin[J]. Gynecol Oncol, 2015, 136 (3): 562-566.
  • 7Abdel-Azeez HA, Labib HA, Sharaf SM, et al. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev, 2010, 11(1): 111-116.
  • 8Kirchhoff C, Haben I, Ilvell R, et al. A major human epidid- lymis- specific cDNA encodes a protein with sequence ho- mology to extracellular proteinase inhibitors [ J]. Biol Re- prod, 1991,45 (2) : 350 - 357.
  • 9Gao L, Cheng HY, Dong L, et al. The role of HE4 in ovarian cancer inhibiting tumour Cell proliferiation and metastasis [J]. J Jnt Med Res,2011,39(5) : 1645 -1660.
  • 10Angioli R, Plotti F, Capriglione S, et ah The role of novel hio- marker HE4 in endometrial cancer :a case control prospec- tive study[ J ]. Tumor Biol,2013.34 ( 1 ) :571 - 576.

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部